Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments.

CONCLUSION: SphK1 and SphK2 have many common features but different and even opposite biological functions. For this reason several research groups are interested in understanding the therapeutic usefulness of a selective or non-selective inhibition of SphKs. Moreover a compensatory mechanism for the two isoforms has been demonstrated thus leading the development of dual inhibitors.
PMID: 30947653 [PubMed - as supplied by publisher]

Source: Current Pharmaceutical Design - April 2, 2019 Category: Drugs & Pharmacology Authors: Magli E, Corvino A, Fiorino F, Frecentese F, Perissutti E, Saccone I, Santagada V, Caliendo G, Severino B Tags: Curr Pharm Des Source Type: research